Recombinant tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is an
antitumor protein that is in clinical trials as a potential anticancer therapy but suffers from drug …

We have identified TNFSF10 (TRAIL) as a p53-transcriptional target gene. There are two p53
DNA-binding sites in the human TNFSF10 promoter region, at 346 and 625 bp upstream of …

TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy
in patients with chronic lymphocytic leukaemia (CLL). We evaluated long‐term efficacy …

Background We previously reported the identification of ONC201/TIC10, a novel small
molecule inducer of the human TRAIL gene that improves efficacy-limiting properties of …

Purpose: Activating PIK3CA genomic alterations are frequent in head and neck squamous
cell carcinoma (HNSCC), and there is an association between phosphoinositide 3-kinase (…

Aims Programmed death-1/programmed death ligand 1 (PD-1/PD-L1) inhibitor therapy is
accompanied by companion or complementary PD-L1 testing in some tumour types. We …

Exposure to total-body radiation induces hematological changes, which can detriment one’s
immune response to wounds and infection. Here, the decreases in blood cell counts after …

Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck
squamous cell carcinoma (HNSCC) and cetuximab, a monoclonal antibody targeting this …

Background: CLL OS rates have improved over the last 20 years (y), starting with the use of
chemotherapy and chemoimmunotherapy (CT/CIT), to the introduction of novel agents such …

Immune system adaptation during spaceflight is a concern in space medicine. Decreased
circulating leukocytes observed during and after space flight infer suppressed immune …